此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

IASO207 Injection for Active Refractory Systemic Lupus Erythematosus (SLE)

2026年5月23日 更新者:Xiangyu Zhao、Peking University People's Hospital

An Exploratory Clinical Study on the Treatment of Active Refractory Systemic Lupus Erythematosus With IASO207 Injection

This is a single-center, open-label, exploratory clinical study designed to evaluate the efficacy and safety of IASO207 Injection (in vivo CAR-T) in patients with active refractory systemic lupus erythematosus.

研究概览

地位

招聘中

详细说明

This study is a single-arm, single-center, open-label, first-in-human (FIH) clinical trial designed to preliminarily evaluate the safety and efficacy of IASO207 injection, an in vivo chimeric antigen receptor T-cell (CAR-T) therapy, in patients with active, refractory systemic lupus erythematosus (SLE), and to determine the recommended dose for subsequent clinical development.

A standard "3+3" dose-escalation design will be employed during the dose-escalation phase, with three predefined dose levels: 5.0 × 10⁸ TU, 1.0 × 10⁹ TU, and 2.0 × 10⁹ TU. Each dose cohort will enroll 3-6 subjects, with a single administration of IASO207 injection.

The primary objective is to assess the safety and tolerability of IASO207 across different dose levels. Secondary and exploratory objectives include the characterization of pharmacokinetics, pharmacodynamics, and immunogenicity, as well as the preliminary evaluation of clinical efficacy in patients with active refractory SLE. The results of this study are expected to inform dose selection and support subsequent clinical trials.

研究类型

介入性

注册 (估计的)

18

阶段

  • 第一阶段早期

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习联系方式

研究联系人备份

学习地点

      • Beijing、中国、100044
        • 招聘中
        • Peking University People's Hospital
        • 副研究员:
          • Meng Lv, M.D, Ph.D
        • 接触:
        • 接触:
        • 首席研究员:
          • Xiangyu Zhao, M.D, Ph.D
        • 首席研究员:
          • Jing He, M.D, Ph.D

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

  • 成人
  • 年长者

接受健康志愿者

不

描述

Inclusion Criteria:

  1. Subjects aged 18-75 years old, regardless of gender.
  2. Subjects diagnosed with active refractory SLE: a) Confirmed by the 2019 European League Against Rheumatism (EULAR)/American College of Rheumatology (ACR) classification criteria or the 2012 Systemic Lupus Erythematosus Collaborative Clinic (SLICC) criteria for at least 24 weeks; b) SLE Disease Activity Index 2000 (SLEDAI-2K) score ≥ 8, with at least 1 organ system having a BILAG-2004 A-class activity score at screening, or 2 organ systems having a BILAG-2004 B-class activity score; c) Previously treated with standardized glucocorticoids and at least two immunosuppressants/adjusters, antimalarial drugs or biologics for at least 3 months.
  3. Positive for disease-related pathogenic antibodies: Anti-nuclear antibody (ANA) positive and/or anti-dsDNA positive and/or anti-Smith positive.
  4. Allowed to use ≤ 20mg/d prednisone or equivalent dose of corticosteroids at screening, and use at a stable dose for at least 2 weeks. Note: Local or inhaled corticosteroids (or its immunomodulators) can be used concurrently;
  5. If antimalarial treatment has been initiated for ≥ 12 weeks before screening and is used at a stable dose for at least 8 weeks, it is allowed to continue in the study (maximum hydroxychloroquine dose ≤ 400mg/d).
  6. If immunosuppressants have been used before screening, they must be used at a stable dose for at least 4 weeks.
  7. Laboratory tests must meet the following conditions: a) Blood routine: Absolute neutrophil count (ANC) ≥ 1.0×10^9/L; Absolute lymphocyte count (ALC) ≥ 0.3×10^9/L; Hemoglobin ≥ 60 g/L; Platelets ≥ 50×10^9/L b) Liver function: Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤ 2.5× upper limit of normal (ULN); Serum total bilirubin ≤ 1.5×ULN (Gilbert's syndrome ≤ 3.0×ULN).
  8. The subject and their spouse agree to take effective contraceptive measures (excluding safe period contraception) from the time of signing the informed consent form by the subject until one year after IASO207 injection treatment.
  9. The subject must agree to sign or personally write and present the signed informed consent form approved by the ethics committee before starting any screening procedure.

Exclusion Criteria:

Disease-related:

  1. Diagnosed with drug-induced SLE.
  2. Complicated with other autoimmune diseases that may affect the assessment of the study, including but not limited to Sjögren's syndrome, psoriasis, rheumatoid arthritis.
  3. Had a catastrophic antiphospholipid syndrome or developed a severe antiphospholipid syndrome within 1 year before screening.
  4. The study disease involved neurological symptoms with a BILAG-2004 activity score of class A.

    Other medical history-related:

  5. Known primary immunodeficiency (congenital or acquired).
  6. The subject has uncontrollable active fungal, viral, bacterial or other infections (existing persistent infection-related signs/symptoms, not improved after appropriate anti-infection treatment) or requires intravenous anti-infection drug treatment for infection.
  7. Positive hepatitis B surface antigen (HBsAg), or positive hepatitis B core antibody (HBcAb) and abnormal peripheral blood hepatitis B virus (HBV) DNA detection (defined as HBV DNA quantification above the normal reference range of the testing center or positive HBV DNA qualitative detection); positive hepatitis C virus (HCV) antibody and positive peripheral blood hepatitis C virus (HCV) RNA; positive Human Immunodeficiency Virus (HIV) antibody; positive cytomegalovirus (CMV) DNA detection; positive Treponema pallidum specific antibody and positive rapid plasma reagin test for syphilis.
  8. Severe heart disease: including but not limited to unstable angina pectoris and/or myocardial infarction within 12 months of screening, any congestive heart failure (NYHA classification ≥ III), and a history of severe arrhythmia; or left ventricular ejection fraction (LVEF) < 45%.
  9. Severe asthma or chronic obstructive pulmonary disease (COPD), with stable treatment considered for mild or moderate asthma or COPD by the investigator and sponsor; or resting arterial blood oxygen saturation < 91%.
  10. Evaluated by the investigator as having a severe bleeding risk.
  11. Evaluated by the investigator as having severe liver dysfunction.
  12. History of severe kidney disease; or eGFR < 30 mL/min/1.73m2 calculated by the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) formula.
  13. Acute cerebrovascular disease events occurred within 6 months before enrollment, including transient ischemic attack or stroke history.
  14. Any severe and/or uncontrolled comorbid diseases as assessed by the investigator.
  15. Had a malignant tumor within 5 years before screening, excluding cured cervical carcinoma in situ, basal cell or squamous cell skin cancer, locally advanced prostate cancer after radical surgery, breast duct carcinoma in situ after radical surgery, or papillary thyroid carcinoma after radical surgery.
  16. Had a clear history of mental disorder or a history of substance abuse for mental disorders that cannot be quit.
  17. Known allergy to the components of IASO207 injection or to the supportive drugs required for the toxicity management of CAR-T cell therapy (such as tocilizumab).

    Previous and concurrent treatments:

  18. History of organ transplantation.
  19. History of autologous or allogeneic stem cell transplantation.
  20. History of cell therapy or CD19-targeted drug treatment.
  21. Received targeted CD20 biologic therapy within 12 weeks before screening, such as rituximab, obinutuzumab.
  22. Received plasma exchange or immunoadsorption treatment within 12 weeks before screening.
  23. Had or planned to have major surgery or surgical treatment caused by any reason within 12 weeks before screening.
  24. Have participated in the treatment of other investigational drugs (except for placebo) within the previous 4 weeks or 5 half-lives (whichever is longer);
  25. Have received a BAFF antagonist, such as belimumab or tixagevimab, within the previous 4 weeks;
  26. Have received live attenuated vaccine within the previous 4 weeks;
  27. Pregnant or lactating women;
  28. Other situations deemed unsuitable for inclusion by the investigators.

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:治疗
  • 分配:不适用
  • 介入模型:单组作业
  • 屏蔽:无(打开标签)

武器和干预

参与者组/臂
干预/治疗
实验性的:IASO207 Injection
IASO207 Injection will be infused at 5.0×10^8 TU or 1.0×10^9 TU or 2.0×10^9 TU after enrollment
IASO207 is a third-generation replication-deficient self-inactivating lentiviral vector that carries the gene encoding a second-generation anti-human CD19 chimeric antigen receptor (CD19 CAR) containing the 4-1BB co-stimulatory factor. IASO207 has been engineered through surface modification of the lentiviral envelope to enable it to selectively bind and transduce T cells within the body, thereby directly generating CD19 CAR-T cells in vivo.

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
Safety endpoint - Adverse Events (AEs)
大体时间:up to 2 years from IASO207 Injection infusion
Incidence and severity of adverse events as assessed by NCI-CTCAE v5.0 (except CRS and ICANS assessed according to the criteria of 2019 ASTCT criteria).
up to 2 years from IASO207 Injection infusion
Safety endpoint - The incidence of dose-limiting toxicity (DLT)
大体时间:28 days from IASO207 Injection infusion
Percentage of participants who experienced DLT within 28 days after IASO207 administration
28 days from IASO207 Injection infusion

次要结果测量

结果测量
措施说明
大体时间
Pharmacokinetic Endpoint - Cmax (viral particle)
大体时间:Up to 7 days from IASO207 Injection infusion
Maximum concentration (Cmax) of viral particle titer in peripheral blood will be observed and calculated.
Up to 7 days from IASO207 Injection infusion
Pharmacokinetic Endpoint - Cmax (VCN)
大体时间:up to 2 years from IASO207 Injection infusion
The maximum concentration (Cmax) of lentiviral vector copy number (VCN) in peripheral blood after infusion.
up to 2 years from IASO207 Injection infusion
Pharmacodynamic Endpoint - Ferritin
大体时间:up to 2 years from IASO207 Injection infusion
Changes in the levels of Ferritin.
up to 2 years from IASO207 Injection infusion
Pharmacodynamic Endpoint - IL-6
大体时间:up to 2 years from IASO207 Injection infusion
Changes in the levels of IL-6.
up to 2 years from IASO207 Injection infusion
Efficacy endpoint - Response rate of SRI-4 after infusion
大体时间:up to 2 years from IASO207 Injection infusion
SLE Responder Index (SRI)-4 is defined as follows with all criteria compared with Baseline: 1. ≥ 4-point reduction in Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI-2K) score. 2. No worsening of the overall condition (< 0.3 point increase in Physician's Global Assessment [PhGA]). 3. No new British Isles Lupus Assessment Group (BILAG) A or more than 1 new BILAG B disease activity scores.
up to 2 years from IASO207 Injection infusion
Efficacy endpoint - lupus low disease activity state (LLDAS) rate through 2 years after infusion
大体时间:up to 2 years from IASO207 Injection infusion
Proportions of subjects achieving LLDAS at each time point
up to 2 years from IASO207 Injection infusion
Efficacy endpoint - Definitions of Remission in SLE (DORIS) rate through 2 years after infusion
大体时间:up to 2 years from IASO207 Injection infusion
Proportions of subjects achieving remission according to the DORIS as assessed by SLEDAI-2K Scale, PhGA score and concomitant medication use
up to 2 years from IASO207 Injection infusion
Efficacy endpoint - The changes in SLEDAI-2K scores
大体时间:up to 2 years from IASO207 Injection infusion
At each visit site, the patients were scored using the SLEDAI-2K, and then the changes in scores compared between each visit point and the baseline score were evaluated
up to 2 years from IASO207 Injection infusion
Efficacy endpoint - The changes in PGA scores
大体时间:up to 2 years from IASO207 Injection infusion
At each visit site, the patients were scored using the PGA, and then the changes in scores compared between each visit point and the baseline score were evaluated
up to 2 years from IASO207 Injection infusion
7. Pharmacokinetic Endpoint - Tmax (viral particle)
大体时间:Up to 7 days from IASO207 Injection infusion
Peak time (Tmax) of viral particle titer in peripheral blood will be observed and analyzed.
Up to 7 days from IASO207 Injection infusion
Pharmacokinetic Endpoint - AUC0-7 (viral particle)
大体时间:Up to 7 days from IASO207 Injection infusion
AUC0-7d refers to the area under the concentration-time curve from day 0 to day 7
Up to 7 days from IASO207 Injection infusion
Pharmacokinetic Endpoint - Cmax (CAR-T cells)
大体时间:up to 2 years from IASO207 Injection infusion
The maximum concentration (Cmax) of CAR-T cells in peripheral blood after infusion
up to 2 years from IASO207 Injection infusion
Pharmacokinetic Endpoint - Tmax (CAR-T cells)
大体时间:up to 2 years from IASO207 Injection infusion
The time for CAR-T cells to reach the maximum concentration (Tmax) after infusion
up to 2 years from IASO207 Injection infusion
Pharmacokinetic Endpoint - AUC (CAR-T cells)
大体时间:up to 2 years from IASO207 Injection infusion
Area under the curve of 28 days, 90 days, 180 days, and the last time point of PK measurement (AUC0-28d, AUC0-90d, AUC0-180d, AUC0-last) for CAR-T cells.
up to 2 years from IASO207 Injection infusion
Pharmacokinetic Endpoint - Tmax (VCN)
大体时间:up to 2 years from IASO207 Injection infusion
The time for VCN to reach the maximum concentration (Tmax) after infusion
up to 2 years from IASO207 Injection infusion
Pharmacokinetic Endpoint - AUC (VCN)
大体时间:up to 2 years from IASO207 Injection infusion
Area under the curve of 28 days, 90 days, 180 days, and the last time point (AUC0-28d, AUC0-90d, AUC0-180d, AUC0-last) for VCN
up to 2 years from IASO207 Injection infusion
Pharmacodynamic Endpoint - Pathogenic antibodies
大体时间:up to 2 years from IASO207 Injection infusion
Changes in serum levels of pathogenic antibodies such as ANA, anti-dsDNA, and anti-Smith.
up to 2 years from IASO207 Injection infusion
Pharmacodynamic Endpoint - Complement levels
大体时间:up to 2 years from IASO207 Injection infusion
Changes in measures of C3, C4.
up to 2 years from IASO207 Injection infusion
Pharmacodynamic Endpoint - Immune cell subsets
大体时间:up to 2 years from IASO207 Injection infusion
Changes in the levels of Immune cell subsets
up to 2 years from IASO207 Injection infusion
Pharmacodynamic Endpoint - Serum immunoglobulin
大体时间:up to 2 years from IASO207 Injection infusion
Changes in serum immunoglobulin (IgG, IgA, IgM) levels from baseline.
up to 2 years from IASO207 Injection infusion
Pharmacodynamic Endpoint - CRP
大体时间:up to 2 years from IASO207 Injection infusion
Changes in the levels of CRP
up to 2 years from IASO207 Injection infusion

其他结果措施

结果测量
措施说明
大体时间
Immunogenicity
大体时间:up to 2 years from IASO207 Injection infusion
Prevalence and titer of confirmed human anti-CAR antibodies in peripheral blood.
up to 2 years from IASO207 Injection infusion
Replication competent lentivirus (RCL)
大体时间:up to 2 years from IASO207 Injection infusion
Prevalence of replication-competent lentivirus (RCL) in peripheral blood.
up to 2 years from IASO207 Injection infusion
Virus shedding
大体时间:Up to 7 days from IASO207 Injection infusion
Presence of viral shedding in body fluid samples (urine, feces, and saliva)
Up to 7 days from IASO207 Injection infusion

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

调查人员

  • 首席研究员:XiangYu Zhao, M.D, Ph.D、Peking University People's Hospital
  • 首席研究员:Jing He, M.D, Ph.D、Peking University People's Hospital

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (估计的)

2026年5月25日

初级完成 (估计的)

2029年5月30日

研究完成 (估计的)

2030年5月30日

研究注册日期

首次提交

2026年5月1日

首先提交符合 QC 标准的

2026年5月23日

首次发布 (实际的)

2026年6月1日

研究记录更新

最后更新发布 (实际的)

2026年6月1日

上次提交的符合 QC 标准的更新

2026年5月23日

最后验证

2026年5月1日

更多信息

与本研究相关的术语

药物和器械信息、研究文件

研究美国 FDA 监管的药品

不

研究美国 FDA 监管的设备产品

不

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅